SRR1332856
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- COAGULATION+0.412
- KRAS_SIGNALING_DN+0.357
- INTERFERON_ALPHA_RESPONSE+0.323
- INTERFERON_GAMMA_RESPONSE+0.295
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.284
- ANGIOGENESIS+0.279
- BILE_ACID_METABOLISM+0.256
- XENOBIOTIC_METABOLISM+0.214
- APICAL_SURFACE+0.213
- IL6_JAK_STAT3_SIGNALING+0.209
Top 10 suppressed
- MYC_TARGETS_V1-0.599
- DNA_REPAIR-0.545
- OXIDATIVE_PHOSPHORYLATION-0.536
- MYC_TARGETS_V2-0.534
- UNFOLDED_PROTEIN_RESPONSE-0.506
- MTORC1_SIGNALING-0.482
- PROTEIN_SECRETION-0.448
- CHOLESTEROL_HOMEOSTASIS-0.422
- E2F_TARGETS-0.384
- PI3K_AKT_MTOR_SIGNALING-0.362
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR819793 | GTEX | — | 0.962 |
| 2 | SRR1330699 | GTEX | — | 0.962 |
| 3 | SRR1456333 | GTEX | — | 0.960 |
| 4 | SRR1444559 | GTEX | — | 0.959 |
| 5 | SRR1389036 | GTEX | — | 0.958 |
| 6 | SRR820292 | GTEX | — | 0.955 |
| 7 | SRR1467011 | GTEX | — | 0.952 |
| 8 | SRR1455698 | GTEX | — | 0.951 |
| 9 | SRR1355613 | GTEX | — | 0.950 |
| 10 | SRR817775 | GTEX | — | 0.950 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| COAGULATION | 0.412 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.357 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.323 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.295 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.284 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.279 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.256 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.214 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.213 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.209 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.204 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.203 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.180 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.170 | Inavolisib | — uncovered |
| COMPLEMENT | 0.142 | Inavolisib | — uncovered |
| MYOGENESIS | 0.139 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.135 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.088 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.084 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.047 | Inavolisib | — uncovered |